<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Nutraceuticals</title>
	<atom:link href="http://www.tapanray.in/tag/nutraceuticals/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Nutraceuticals: Still An Oasis Amidst Well-Regulated Pharmaceuticals</title>
		<link>http://www.tapanray.in/nutraceuticals-still-an-oasis-amidst-well-regulated-pharmaceuticals/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=nutraceuticals-still-an-oasis-amidst-well-regulated-pharmaceuticals</link>
		<comments>http://www.tapanray.in/nutraceuticals-still-an-oasis-amidst-well-regulated-pharmaceuticals/#comments</comments>
		<pubDate>Sun, 27 Nov 2016 23:34:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[evidence]]></category>
		<category><![CDATA[foods]]></category>
		<category><![CDATA[formulations]]></category>
		<category><![CDATA[FSSAI]]></category>
		<category><![CDATA[functional]]></category>
		<category><![CDATA[Gray]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[nutritional]]></category>
		<category><![CDATA[Oasis]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[phytochemical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulated]]></category>
		<category><![CDATA[Space]]></category>
		<category><![CDATA[supplement]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tweaking]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7987</guid>
		<description><![CDATA[On November 24, 2016, the food-safety watchdog of India announced that health supplements or Nutraceuticals cannot be sold as &#8216;medicines&#8217; anymore. This new regulatory standard has been set for the manufacturers of Nutraceuticals and food supplements, and is aimed at &#8230; <a href="http://www.tapanray.in/nutraceuticals-still-an-oasis-amidst-well-regulated-pharmaceuticals/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/nutraceuticals-still-an-oasis-amidst-well-regulated-pharmaceuticals/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>PE Investment In Pharma: The Changing Need Of Due Diligence</title>
		<link>http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pe-investment-in-pharma-the-changing-need-of-due-diligence</link>
		<comments>http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/#comments</comments>
		<pubDate>Mon, 02 May 2016 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Directors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[due diligence]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[FSSAI]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[good]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Independent]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[Investor]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[PE]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[promoters]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7621</guid>
		<description><![CDATA[From an international perspective, a Bain &#38; Company report of April 2016 highlighted setting a new healthcare M&#38;A record in the year 2015. During this year the total deal value was over 2.5 times higher than the average annual deal value &#8230; <a href="http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nutraceuticals: Make The Fragile Regulatory Space Robust, Soon</title>
		<link>http://www.tapanray.in/nutraceuticals-make-the-fragile-regulatory-space-robust-soon/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=nutraceuticals-make-the-fragile-regulatory-space-robust-soon</link>
		<comments>http://www.tapanray.in/nutraceuticals-make-the-fragile-regulatory-space-robust-soon/#comments</comments>
		<pubDate>Mon, 11 Apr 2016 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[Food]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[FSSAI]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[mass]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[phytochemical]]></category>
		<category><![CDATA[phytopharmaceutical]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Revital]]></category>
		<category><![CDATA[supplements]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TV]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7591</guid>
		<description><![CDATA[In the space between drugs and nutrition, there is an intriguing ‘gray area’ with significant business relevance, especially in India. In a related publication, A.T. Kearney &#8211; a leading global management consulting firm has elaborated it as below: “At one end &#8230; <a href="http://www.tapanray.in/nutraceuticals-make-the-fragile-regulatory-space-robust-soon/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/nutraceuticals-make-the-fragile-regulatory-space-robust-soon/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nutraceuticals: A Major Regulatory Step That Was Long Overdue</title>
		<link>http://www.tapanray.in/nutraceuticals-a-major-regulatory-step-that-was-long-overdue/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=nutraceuticals-a-major-regulatory-step-that-was-long-overdue</link>
		<comments>http://www.tapanray.in/nutraceuticals-a-major-regulatory-step-that-was-long-overdue/#comments</comments>
		<pubDate>Mon, 21 Dec 2015 00:00:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2006]]></category>
		<category><![CDATA[ASSOCHAM]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Food Safety & Standards Act]]></category>
		<category><![CDATA[gazette]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[pharmacodynamics]]></category>
		<category><![CDATA[pharmacokinetics]]></category>
		<category><![CDATA[phytochemical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[RNCOS]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7346</guid>
		<description><![CDATA[Currently in India the nutraceutical products segment, with surrogate or off-label therapeutic claims, is growing at a reasonable pace. Many such products are now being directly promoted to the medical profession, just like any other modern medicines, with therapeutic claims &#8230; <a href="http://www.tapanray.in/nutraceuticals-a-major-regulatory-step-that-was-long-overdue/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/nutraceuticals-a-major-regulatory-step-that-was-long-overdue/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nutraceuticals: An Emerging Opportunity in The Gray Area Between Pharma And Nutrition</title>
		<link>http://www.tapanray.in/nutraceuticals-an-emerging-opportunity-in-the-gray-area-between-pharma-and-nutrition/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=nutraceuticals-an-emerging-opportunity-in-the-gray-area-between-pharma-and-nutrition</link>
		<comments>http://www.tapanray.in/nutraceuticals-an-emerging-opportunity-in-the-gray-area-between-pharma-and-nutrition/#comments</comments>
		<pubDate>Mon, 17 Nov 2014 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[A.T.Kearney]]></category>
		<category><![CDATA[area]]></category>
		<category><![CDATA[Ayush]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Coca]]></category>
		<category><![CDATA[Cola]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[dietary]]></category>
		<category><![CDATA[EBM]]></category>
		<category><![CDATA[EBN]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[evidence]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Frost&Sullivan]]></category>
		<category><![CDATA[FSSA]]></category>
		<category><![CDATA[FSSAI]]></category>
		<category><![CDATA[Gray]]></category>
		<category><![CDATA[Homeopathy]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Naturopathy]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[nutrition]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Siddha]]></category>
		<category><![CDATA[supplement]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[Unani]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Yoga]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6190</guid>
		<description><![CDATA[Close association between nutrition and health has assumed a historical relevance. Growing pieces of evidence, even today, suggests that nutritional intervention with natural substances could play an important role, especially in the preventive healthcare. The World Health Organization (WHO) too &#8230; <a href="http://www.tapanray.in/nutraceuticals-an-emerging-opportunity-in-the-gray-area-between-pharma-and-nutrition/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/nutraceuticals-an-emerging-opportunity-in-the-gray-area-between-pharma-and-nutrition/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nutraceuticals with Therapeutic Claims: A Vulnerable Growing Bubble Protected by Faith and Hope of Patients</title>
		<link>http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients</link>
		<comments>http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/#comments</comments>
		<pubDate>Mon, 27 Aug 2012 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Bubble]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[Claims]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[Faith]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hope]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Protected]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[Vulnerable]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=45</guid>
		<description><![CDATA[Today a growing number of particularly the aging population wants to live a healthy life without consuming much of chemical drugs, which in turn is becoming a key growth driver for nutraceutical products across the world. Further, increasing interest towards &#8230; <a href="http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sanofi&#8217;s acquisition of Universal Medicare could redefine nutraceuticals business in India</title>
		<link>http://www.tapanray.in/sanofis-acquisition-of-universal-medicare-could-redefine-nutraceuticals-business-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=sanofis-acquisition-of-universal-medicare-could-redefine-nutraceuticals-business-in-india</link>
		<comments>http://www.tapanray.in/sanofis-acquisition-of-universal-medicare-could-redefine-nutraceuticals-business-in-india/#comments</comments>
		<pubDate>Mon, 12 Sep 2011 00:30:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[could]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[redefine]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=203</guid>
		<description><![CDATA[The Economic Times in its August 24, 2011 edition reported that Sanofi-Aventis has acquired the nutraceuticals business of Universal Medicare to scale up their business operations in the ‘wellness’ space of the healthcare sector in India. What are ‘Nutraceuticals’? Dr. &#8230; <a href="http://www.tapanray.in/sanofis-acquisition-of-universal-medicare-could-redefine-nutraceuticals-business-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/sanofis-acquisition-of-universal-medicare-could-redefine-nutraceuticals-business-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
